CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA : vimarsana.com

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market.

Related Keywords

United States , China , Beijing , Japan , Wuxi , Jiangsu , Chinese , Rui Zhang , Acrotech Biopharma Inc , National Medical Products Administration , European Medicines Agency , Pharmaceuticals Wuxi Co Ltd , Pharmaceuticals Inc , Drug Administration , Exchange Commission , Pharmaceuticals China Co Ltd , Greater China , Securities Litigation Reform Act , Nasdaq Capital Market , Medical Products Administration , Clin Risk , Chinese Patients , Refractory Peripheralt Cell Lymphoma , Clin Oncol , The Company , Pharmaceutical Products , Iasi , Ommercialization , Harmaceuticals , Orward Looking Statements , Orward Looking Statement , Ralatrexate ,